In the past week, HEPA stock has gone up by 25.88%, with a monthly gain of 10.96% and a quarterly plunge of -26.57%. The volatility ratio for the week is 16.10%, and the volatility levels for the last 30 days are 9.32% for Hepion Pharmaceuticals Inc. The simple moving average for the past 20 days is 15.83% for HEPA’s stock, with a -48.13% simple moving average for the past 200 days.
Is It Worth Investing in Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Right Now?
The stock has a 36-month beta value of 1.82. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HEPA is 5.79M, and at present, short sellers hold a 0.43% of that float. On October 18, 2024, the average trading volume of HEPA was 152.08K shares.
HEPA) stock’s latest price update
Hepion Pharmaceuticals Inc (NASDAQ: HEPA)’s stock price has gone rise by 24.83 in comparison to its previous close of 0.60, however, the company has experienced a 25.88% increase in its stock price over the last five trading days. globenewswire.com reported 2024-09-04 that KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) — Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (“Hepion”), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today jointly announced the filing of a registration statement of Pharma Two B on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”).
Analysts’ Opinion of HEPA
Many brokerage firms have already submitted their reports for HEPA stocks, with ROTH Capital repeating the rating for HEPA by listing it as a “Buy.” The predicted price for HEPA in the upcoming period, according to ROTH Capital is $14 based on the research report published on July 20, 2020 of the previous year 2020.
HEPA Trading at 8.40% from the 50-Day Moving Average
After a stumble in the market that brought HEPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.87% of loss for the given period.
Volatility was left at 9.32%, however, over the last 30 days, the volatility rate increased by 16.10%, as shares surge +10.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +31.17% upper at present.
During the last 5 trading sessions, HEPA rose by +25.88%, which changed the moving average for the period of 200-days by -76.22% in comparison to the 20-day moving average, which settled at $0.6466. In addition, Hepion Pharmaceuticals Inc saw -76.88% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HEPA starting from Wijngaard Peter, who purchase 2,500 shares at the price of $3.09 back on Nov 24 ’23. After this action, Wijngaard Peter now owns 7,001 shares of Hepion Pharmaceuticals Inc, valued at $7,725 using the latest closing price.
Wijngaard Peter, the Director of Hepion Pharmaceuticals Inc, purchase 2,500 shares at $3.05 during a trade that took place back on Nov 27 ’23, which means that Wijngaard Peter is holding 9,501 shares at $7,625 based on the most recent closing price.
Stock Fundamentals for HEPA
Current profitability levels for the company are sitting at:
- -316.77 for the present operating margin
- 0.44 for the gross margin
The net margin for Hepion Pharmaceuticals Inc stands at -258.5. The total capital return value is set at -6.9. Equity return is now at value -189.52, with -133.45 for asset returns.
Based on Hepion Pharmaceuticals Inc (HEPA), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -225.74. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -874.51.
Currently, EBITDA for the company is -45.19 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 21.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.62.
Conclusion
To sum up, Hepion Pharmaceuticals Inc (HEPA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
